Safety Experience With Bosentan in 146 Children 2

Safety Experience With Bosentan in 146 Children 2–11 Years Old ...

Safety experience with bosentan in 146 children 2-11 ... - PubMed

The discontinuation rate was 14.4% in children versus 28.1% in patients > or =12 y. The Tracleer PMS results provide unique information on pediatric PAH in ...

Safety Experience With Bosentan in 146 Children 2–11 Years Old ...

The oral dual endothelin receptor antagonist bosentan has been shown to improve the short- and medium-term course of adult pulmonary arterial hypertension ...

Safety experience with bosentan in 146 children 2-11 years old with ...

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance ...

Safety Experience With Bosentan in 146 Children 2–11 Years Old ...

Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance ...

(PDF) Safety experience with bosentan in 146 children 2-11 years ...

Abstract: The oral dual endothelin receptor antagonist bosentan has been shown to improve the short- and medium-term course of adult pulmonary arterial ...

Safety experience with bosentan in 146 children 2-11 years old with ...

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance ...

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial ...

Safety experience with bosentan in 146 children 2–11 years old with pulmonary arterial hypertension: results from the European postmarketing ...

11 Use of Bosentan in Pediatric Pulmonary Hypertension

Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the ...

Effects of Long-Term Bosentan in Children With Pulmonary Arterial ...

Bosentan, an oral endothelin ETA/ETBreceptor antagonist, improves hemodynamics and exercise capacity in adults with PAH; however, limited data are available on ...

Long-term efficacy of bosentan in treatment of pulmonary arterial ...

10 children were successfully maintained on bosentan for 5 yrs, with half receiving the drug as a monotherapy. The drug appeared safe, in that the aspartate ...

Treatment of pulmonary arterial hypertension in children - Gorenflo

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance ...

Inpharma 1656 - 20 Sep 2008 Bosentan better tolerated in children ...

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing. Surveillance ...

Pharmacokinetic and clinical profile of a novel formulation of ...

Exposure to bosentan was lower in paediatric pulmonary arterial hypertension (PAH) patients treated with the marketed adult formulation at a dose of about 2 mg ...

Effects of Long-Term Bosentan in Children With Pulmonary Arterial ...

Three children weighed <10 kg at bosentan treatment initiation and received 15.6 mg b.i.d. One-half of the target dose was administered daily during the first ...

Pulmonary Hypertension in Infants, Children, and Young Adults

Beghetti, M.M. Hoeper, D.G. Kiely, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from ...

Advances in the Management of Pediatric Pulmonary Hypertension ...

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance ...

Advances in the Management of Pediatric Pulmonary Hypertension

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing ...

Assessment of endpoints in the pediatric population ... - Lippincott

Safety experience with bosentan in 146 children 2–11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance ...

Safety and Tolerability of Targeted Therapies for Pulmonary ...

trend toward increased mortality in patients\2 years old ... Segal ES, Humbert M (2008) Safety experience with bosentan in. 146 children 2–11 ...

(PDF) Safety and Tolerability of Targeted Therapies for Pulmonary ...

Nine severe adverse reactions (10 %) occurred, requiring eight treatment withdrawal and one hospital admission. Treatment with targeted therapies for pulmonary ...